Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $2.2 million.

  • Seres Therapeutics' Free Cash Flow rose 10631.45% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.4 million, marking a year-over-year increase of 8524.68%. This contributed to the annual value of -$149.0 million for FY2024, which is 1887.83% down from last year.
  • According to the latest figures from Q3 2025, Seres Therapeutics' Free Cash Flow is $2.2 million, which was up 10631.45% from -$13.4 million recorded in Q2 2025.
  • In the past 5 years, Seres Therapeutics' Free Cash Flow ranged from a high of $123.6 million in Q3 2021 and a low of -$80.7 million during Q1 2023
  • For the 5-year period, Seres Therapeutics' Free Cash Flow averaged around -$26.3 million, with its median value being -$39.9 million (2024).
  • Data for Seres Therapeutics' Free Cash Flow shows a peak YoY increase of 57682.4% (in 2021) and a maximum YoY decrease of 19439.21% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Seres Therapeutics' Free Cash Flow stood at -$53.4 million in 2021, then decreased by 5.45% to -$56.4 million in 2022, then grew by 14.16% to -$48.4 million in 2023, then increased by 19.44% to -$39.0 million in 2024, then surged by 105.64% to $2.2 million in 2025.
  • Its Free Cash Flow was $2.2 million in Q3 2025, compared to -$13.4 million in Q2 2025 and $26.9 million in Q1 2025.